




Searching News Database: diabetic neuropathy
HSMN NewsFeed - 26 Jan 2023
FDA Approves Abbott's Spinal Cord Stimulation for People Living with Painful Diabetic Peripheral Neuropathy
FDA Approves Abbott's Spinal Cord Stimulation for People Living with Painful Diabetic Peripheral Neuropathy
HSMN NewsFeed - 1 Sep 2022
Nevro Announces Multiple Positive Coverage Updates for the Treatment of Painful Diabetic Neuropathy
Nevro Announces Multiple Positive Coverage Updates for the Treatment of Painful Diabetic Neuropathy
HSMN NewsFeed - 4 Nov 2021
NeuroBo Pharmaceuticals Appoints Gil Price, M.D. as President and Chief Executive Officer
NeuroBo Pharmaceuticals Appoints Gil Price, M.D. as President and Chief Executive Officer
HSMN NewsFeed - 2 Sep 2020
NeuroBo Pharmaceuticals Appoints Douglas J. Swirsky to the Board of Directors
NeuroBo Pharmaceuticals Appoints Douglas J. Swirsky to the Board of Directors
HSMN NewsFeed - 3 Jun 2014
Spinifex Pharmaceuticals Appoints Neuroscience Expert Dr Ronald Marcus as Chief Medical Officer
Spinifex Pharmaceuticals Appoints Neuroscience Expert Dr Ronald Marcus as Chief Medical Officer
HSMN NewsFeed - 27 May 2014
Spinifex Pharmaceuticals Strengthens Scientific Advisory Board (SAB) with Experts in Chronic Pain
Spinifex Pharmaceuticals Strengthens Scientific Advisory Board (SAB) with Experts in Chronic Pain
HSMN NewsFeed - 3 Dec 2013
BioDelivery Sciences Announces Hiring of David Acheson as Vice President of Sales and Managed Markets
BioDelivery Sciences Announces Hiring of David Acheson as Vice President of Sales and Managed Markets
HSMN NewsFeed - 29 Nov 2012
NeuroMetrix Completes 510(k) Clearance Process for SENSUS(TM) Pain Management System
NeuroMetrix Completes 510(k) Clearance Process for SENSUS(TM) Pain Management System
HSMN NewsFeed - 17 Jul 2009
NeurogesX Announces Resignation of Bruce A. Peacock from Board of Directors
NeurogesX Announces Resignation of Bruce A. Peacock from Board of Directors
HSMN NewsFeed - 2 Jun 2009
NeurogesX Receives FDA Orphan Drug Designation for Qutenza(TM) for Treatment of Postherpetic Neuralgia
NeurogesX Receives FDA Orphan Drug Designation for Qutenza(TM) for Treatment of Postherpetic Neuralgia
HSMN NewsFeed - 19 Mar 2009
NeurogesX' Qutenza(TM) (NGX-4010) Receives Positive Committee Recommendation in European Union
NeurogesX' Qutenza(TM) (NGX-4010) Receives Positive Committee Recommendation in European Union
HSMN NewsFeed - 22 Oct 2008
NeurogesX Submits NDA for NGX-4010 Dermal Capsaicin Patch for Treatment of Postherpetic Neuralgia (PHN)
NeurogesX Submits NDA for NGX-4010 Dermal Capsaicin Patch for Treatment of Postherpetic Neuralgia (PHN)
HSMN NewsFeed - 10 Jun 2008
Roche Moves Investigational Diabetes Drug, Taspoglutide, Into Phase III Clinical Trials
Roche Moves Investigational Diabetes Drug, Taspoglutide, Into Phase III Clinical Trials
HSMN NewsFeed - 27 Feb 2008
OVATION Appoints Christopher Silber, M.D. as Vice President, Clinical Affairs
OVATION Appoints Christopher Silber, M.D. as Vice President, Clinical Affairs
HSMN NewsFeed - 29 Nov 2007
UCB Announces FDA Filing for lacosamide in the Treatment of Diabetic Neuropathic Pain
UCB Announces FDA Filing for lacosamide in the Treatment of Diabetic Neuropathic Pain
HSMN NewsFeed - 27 Sep 2007
NeurogesX' NGX-4010 MAA Filed and Accepted for Review by EMEA for Treatment of Peripheral Neuropathic Pain
NeurogesX' NGX-4010 MAA Filed and Accepted for Review by EMEA for Treatment of Peripheral Neuropathic Pain
HSMN NewsFeed - 4 Sep 2007
NeurogesX Announces Positive Results from Second Phase 3 Clinical Trial in Postherpetic Neuralgia
NeurogesX Announces Positive Results from Second Phase 3 Clinical Trial in Postherpetic Neuralgia
HSMN NewsFeed - 14 Aug 2007
BDSI Names David Blum, M.D. Vice President of Medical Affairs and Clinical Research
BDSI Names David Blum, M.D. Vice President of Medical Affairs and Clinical Research
HSMN NewsFeed - 6 Aug 2007
Pfizer Says Growth in Phase II Portfolio Supports Goal of Tripling Phase III Portfolio by 2009
Pfizer Says Growth in Phase II Portfolio Supports Goal of Tripling Phase III Portfolio by 2009
HSMN NewsFeed - 11 Jun 2007
NeurogesX Completes Enrollment in Phase 3 Clinical Trial for Postherpetic Neuralgia
NeurogesX Completes Enrollment in Phase 3 Clinical Trial for Postherpetic Neuralgia
HSMN NewsFeed - 3 May 2007
Data Suggest Cymbalta(R) Reduced Severity of Night Pain in Patients with Diabetic Nerve Pain
Data Suggest Cymbalta(R) Reduced Severity of Night Pain in Patients with Diabetic Nerve Pain
HSMN NewsFeed - 18 Apr 2007
Avanir Pharmaceuticals Announces Positive Results of Phase III Study for Zenvia in Diabetic Neuropathic Pain
Avanir Pharmaceuticals Announces Positive Results of Phase III Study for Zenvia in Diabetic Neuropathic Pain
HSMN NewsFeed - 12 Feb 2007
AVANIR Pharmaceuticals Hires Martin J. Sturgeon as Vice President and Chief Accounting Officer
AVANIR Pharmaceuticals Hires Martin J. Sturgeon as Vice President and Chief Accounting Officer
HSMN NewsFeed - 30 Jan 2007
AVANIR Receives FDA Approvable Letter for New Formulation of Currently Marketed Antipsychotic Drug FazaClo
AVANIR Receives FDA Approvable Letter for New Formulation of Currently Marketed Antipsychotic Drug FazaClo
HSMN NewsFeed - 18 Oct 2006
NeurogesX Phase 3 Study in Post-Herpetic Neuralgia Meets Primary Endpoint
NeurogesX Phase 3 Study in Post-Herpetic Neuralgia Meets Primary Endpoint
HSMN NewsFeed - 10 Oct 2006
Corautus Genetics Announces Final Efficacy Results of GENASIS Phase IIb Clinical Trial
Corautus Genetics Announces Final Efficacy Results of GENASIS Phase IIb Clinical Trial
HSMN NewsFeed - 7 Aug 2006
AVANIR Pharmaceuticals Hires Theresa Hope-Reese as Vice President of Human Resources
AVANIR Pharmaceuticals Hires Theresa Hope-Reese as Vice President of Human Resources
HSMN NewsFeed - 13 Jul 2006
Corautus Genetics Announces Partial Lifting of FDA Clinical Hold and Update on GENASIS Database Lock
Corautus Genetics Announces Partial Lifting of FDA Clinical Hold and Update on GENASIS Database Lock
HSMN NewsFeed - 13 Jun 2006
NeurogesX Completes Enrollment in Pivotal Phase 3 Postherpetic Neuralgia Trial
NeurogesX Completes Enrollment in Pivotal Phase 3 Postherpetic Neuralgia Trial
HSMN NewsFeed - 4 May 2006
Cephalon's Fentanyl Effervescent Buccal Tablet Reduces Intensity of Breakthrough Pain in Cancer Patients
Cephalon's Fentanyl Effervescent Buccal Tablet Reduces Intensity of Breakthrough Pain in Cancer Patients
HSMN NewsFeed - 10 Apr 2006
Corautus Announces Termination of Patient Enrollment in GENASIS Severe Angina Clinical Trial
Corautus Announces Termination of Patient Enrollment in GENASIS Severe Angina Clinical Trial
HSMN NewsFeed - 14 Feb 2006
Study Finds Cymbalta(R) Was As Safe And Well-Tolerated As Routine Drug Treatments For Diabetic Nerve Pain
Study Finds Cymbalta(R) Was As Safe And Well-Tolerated As Routine Drug Treatments For Diabetic Nerve Pain
Additional items found! 38

Members Archive contains
38 additional stories matching:
diabetic neuropathy
(Password required)
diabetic neuropathy
(Password required)